Emerging research links post-meal blood sugar spikes with higher Alzheimer’s risk, highlighting glucose control, insulin resistance management, and lifestyle interventions as important strategies for brain health.

High-accuracy Alzheimer’s blood tests using biomarkers like p-tau217 may enable earlier, more accessible diagnosis, improving treatment access, precision staging, and personalized neurodegenerative care worldwide.

Estradiol patch shows comparable efficacy to oral hormone therapy for menopause symptoms, offering a convenient transdermal option that may improve safety, adherence, and personalized treatment choices.

Circulating tumor DNA helps detect minimal residual disease and predict recurrence risk in early breast cancer, but its role in guiding treatment decisions remains promising yet unproven.

Point-of-care HCV RNA testing enables same-visit diagnosis and treatment, improving cure rates, reducing transmission, and proving cost-effective by minimizing follow-up loss and long-term complications.

Hepatitis C virus (HCV) RNA testing at the point of care is emerging as a practical way to identify and treat people living with HCV more quickly. As direct-acting antiviral drugs make cure routine, the real bottleneck has shifted to identifying who is infected and getting them started on treatment without losing them between appointments.

CYP2C19 genetic testing is emerging as a practical tool to tailor antiplatelet therapy for people who need blood thinners after a heart attack, stent placement, or other vascular events. Clinicians are starting to use simple genetic results to decide whether the standard drug will work or whether a different medicine is safer and more effective for an individual patient.

Warfarin self-management empowers patients to monitor INR and adjust dosing, improving control and outcomes while reducing clinic burden, though requiring careful training, oversight, and equitable access.

Men’s mental health is often overlooked due to stigma around emotional expression, delaying support and increasing risk of crisis, highlighting need for proactive, normalized, and accessible care strategies.

The Food and Drug Administration updated Prismaflex guidance highlights tubing-related risks, urging vigilance to prevent air-in-blood events and ensure safe, uninterrupted renal replacement therapy in critical care settings.